BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Early stage cardio data from Verve bump the stock
Positive early stage data for Verve Therapeutics Inc.’s base editing therapy points to a range of development options, including bringing partner Eli Lilly and Co. in a...

More in BioWorld

BioWorld MedTech

Edwards lands first CE mark for transfemoral mitral valve replacement
Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease...

More in BioWorld MedTech

BioWorld Science

Pretzel Therapeutics narrows the therapeutic gap for PolG disease
Researchers from Pretzel Therapeutics Inc. and the University of Gothenburg have published new insights on how mutations in the POLG gene affect its functionality and are...

More in BioWorld Science

BioWorld Asia

ABL lands £2B deal with GSK based on BBB passing drug platform
ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.